PDCD1 and glioblastoma: Currently, several IDO-1 inhibitors including epacadostat, navoximod and BMS-986205 [13] are under clinical evaluation and the results are promising using IDO1 inhibitors in combination with anti-PD1 drugs in preclinical models of GBM [14].